Cochrane · systematic review · CD008079
Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia
Bauer, K, Rancea, M, Roloff, V, et al. · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
7
No studies
1
Included studies
NR
No studies 1 · 10%Ungraded 2 · 20%Very low 0 · 0%Low 2 · 20%Moderate 4 · 40%High 1 · 10%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: newly diagnosed or relapsed patients with CLL
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
OS (at 3 years) | HR 0.78 [0.62, 0.98] | 3 studies · 1421 participants | High |
PFS (at 3 years) | HR 0.64 [0.55, 0.74] | 3 studies · 1421 participants | Moderate Downgraded: risk of bias |
TRM | RR 1.19 [0.7, 2.01] | 3 studies · 1415 participants | Moderate Downgraded: risk of bias |
SAEs ‐ overall analysis | RR 1.05 [0.89, 1.23] | 2 studies · 598 participants | Low Downgraded: risk of bias |
Grade 3/4 AEs ‐ overall analysis | RR 1.15 [1.08, 1.23] | 3 studies · 1398 participants | Moderate Downgraded: risk of bias |
Comparison
Population: newly diagnosed or relapsed patients with CLL
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
OS not reported | no estimate extracted | NR | No studies |
PFS not reported | no estimate extracted | 0 participants | Ungraded |
Time to next treatment | no estimate extracted | 0 participants | Ungraded |
CRR | RR 1.18 [0.93, 1.49] | 2 studies · 170 participants | Moderate |
TRM | RR 0.31 [0.06, 1.51] | 2 studies · 177 participants | Low |